Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Linde
LIN
|
+$299M |
| 2 |
General Dynamics
GD
|
+$129M |
| 3 |
Cigna
CI
|
+$86.9M |
| 4 |
CVS Health
CVS
|
+$75M |
| 5 |
Amazon
AMZN
|
+$46.9M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
+$234M |
| 2 |
Northrop Grumman
NOC
|
+$218M |
| 3 |
ESRX
Express Scripts Holding Company
ESRX
|
+$170M |
| 4 |
PX
Praxair Inc
PX
|
+$168M |
| 5 |
COL
Rockwell Collins
COL
|
+$116M |
Sector Composition
| 1 | Technology | 18.92% |
| 2 | Healthcare | 16.26% |
| 3 | Consumer Discretionary | 11.53% |
| 4 | Communication Services | 10.14% |
| 5 | Industrials | 9.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Tyson Foods
TSN
$19.9B
| $55.4M | 0.07% |
1,038,065
+13,200
| +1% | +$705K |
|
277
Microchip Technology
MCHP
$34.9B
| $55.1M | 0.07% |
1,532,618
+31,800
| +2% | +$1.14M |
|
278
Ferrari
RACE
$85.5B
| $55.1M | 0.07% |
554,940
+4,107
| +0.7% | +$408K |
|
|
XYZ
279
Block, Inc.
XYZ
$45.3B
| $55M | 0.07% |
980,500
+55,000
| +6% | +$3.08M |
|
280
Teva Pharmaceuticals
TEVA
$22.9B
| $54.5M | 0.07% |
3,534,099
+31,300
| +0.9% | +$483K |
|
281
Labcorp
LH
$23.1B
| $54.4M | 0.07% |
500,840
+2,677
| +0.5% | +$291K |
|
282
Weyerhaeuser
WY
$18.7B
| $53.9M | 0.07% |
2,464,820
+48,200
| +2% | +$1.05M |
|
283
Corpay
CPAY
$22.1B
| $53.4M | 0.07% |
287,500
+1,400
| +0.5% | +$260K |
|
284
CGI
GIB
$20.8B
| $53.4M | 0.07% |
872,000
-23,200
| -3% | -$1.42M |
|
285
Nucor
NUE
$33.1B
| $53.3M | 0.07% |
1,028,261
+12,900
| +1% | +$668K |
|
286
Royal Caribbean
RCL
$95.9B
| $53.2M | 0.07% |
543,838
+3,100
| +0.6% | +$303K |
|
287
Global Payments
GPN
$20.8B
| $53M | 0.07% |
514,269
+5,000
| +1% | +$516K |
|
288
Aptiv
APTV
$18.2B
| $53M | 0.07% |
861,300
+16,200
| +2% | +$997K |
|
289
Cooper Companies
COO
$13.6B
| $53M | 0.07% |
833,200
+8,400
| +1% | +$534K |
|
290
ResMed
RMD
$40.2B
| $52.9M | 0.07% |
464,200
+8,600
| +2% | +$979K |
|
291
Henry Schein
HSIC
$8.4B
| $52.8M | 0.07% |
858,098
+2,805
| +0.3% | +$173K |
|
292
Idexx Laboratories
IDXX
$51.7B
| $52.4M | 0.07% |
281,700
+4,400
| +2% | +$818K |
|
293
TransDigm Group
TDG
$72.8B
| $52.4M | 0.07% |
154,000
+3,300
| +2% | +$1.12M |
|
294
Align Technology
ALGN
$9.85B
| $52M | 0.07% |
248,200
+5,100
| +2% | +$1.07M |
|
295
Federal Realty Investment Trust
FRT
$8.74B
| $51.9M | 0.07% |
439,822
+1,000
| +0.2% | +$118K |
|
296
Hartford Financial Services
HIG
$37.2B
| $51.8M | 0.07% |
1,166,015
+22,700
| +2% | +$1.01M |
|
297
Pembina Pipeline
PBA
$22.6B
| $51.8M | 0.07% |
1,745,593
-14,900
| -0.8% | -$442K |
|
298
L3Harris
LHX
$52.1B
| $51.4M | 0.07% |
381,556
+2,600
| +0.7% | +$350K |
|
299
Magna International
MGA
$13.2B
| $51.1M | 0.07% |
1,125,100
-51,600
| -4% | -$2.34M |
|
300
Ametek
AME
$44B
| $51.1M | 0.07% |
754,393
+15,000
| +2% | +$1.02M |
|